Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Oncology Reports|April 6, 2005
Immunological evaluation of personalized peptide vaccination for patients with pancreatic cancerKoutaro Yamamoto, Takashi Mine, Kazuko Katagiri, et al.
International Journal of Oncology|February 7, 2012
Personalized peptide vaccination in patients with refractory non-small cell lung cancerKoichi Yoshiyama, Yasuhiro Terazaki, Satoko Matsueda, et al.
Plos One|February 26, 2013
Identification of special AT-rich sequence binding protein 1 as a novel tumor antigen recognized by CD8+ T cells: implication for cancer immunotherapyMingjun Wang, Bingnan Yin, Satoko Matsueda, et al.
International Journal of Oncology|July 26, 2006
Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patientsShigenori Homma, Mamoru Harada, Hirohisa Yano, et al.
Cancer Immunology, Immunotherapy : CII|February 10, 2015
Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppressionMasanori Noguchi, Gaku Arai, Kazumasa Matsumoto, et al.
Anticancer Research|July 15, 2009
N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cellsSatoko Matsueda, Hui Gao, Clayton L Efferson, et al.
Cancer Science|February 12, 2017
A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancerTakahisa Shirahama, Daisuke Muroya, Satoko Matsueda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2011
Targeting human B-cell malignancies through Ig light chain-specific cytotoxic T lymphocytesJinsheng Weng, Soung-Chul Cha, Satoko Matsueda, et al.
Immunity|June 28, 2011
NLRX1 negatively regulates TLR-induced NF-κB signaling by targeting TRAF6 and IKKXiaojun Xia, Jun Cui, Helen Y Wang, et al.
Cancer Science|July 9, 2013
Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patientsRyuji Takahashi, Yukinao Ishibashi, Koji Hiraoka, et al.
Pageof 9